Search the Newsreel

Why is Abcellera Biologics stock surging today?

Abcellera Biologics (ABCL) stock surged over 30% in pre-open trading after its antibody, ABCL 635, met the primary efficacy endpoint in a Phase 2 clinical trial for menopausal hot flashes, showing an 83% reduction in frequency. This clinical success, combined with strong analyst conviction …

AbCellera's ABCL635 Delivers Strong Phase 2 Data; Stock Jumps 33%

(RTTNews) - AbCellera Biologics Inc. (ABCL) announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, an investigational NK3R antagonist antibody for moderate-to-severe vasomotor symptoms due to menopause. The study met its primary efficacy endpoints achieving statistically …

AbCellera’s ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial

AbCellera Biologics announced positive top-line results from its Phase II trial of ABCL-635, a non-hormonal treatment for menopausal hot flashes. The study showed an 83% reduction in moderate-to-severe hot flashes, along with improvements in symptom severity and sleep disturbance, and a favorable tolerability profile. …

Scotiabank Issues Positive Forecast for Millicom International Cellular (NASDAQ:TIGO) Stock Price

Scotiabank raised its price target for Millicom International Cellular (NASDAQ:TIGO) to $60.10 from $52.40, though it maintained a "sector underperform" rating, indicating a potential downside of 38.13% from the current stock price. Despite this, the company reported strong quarterly earnings, beating consensus estimates with …

ABCL Stock Rips As Vertex Deal And Data Catalyst Fire Up Traders

AbCellera Biologics Inc. (ABCL) stock surged over 24% due to strong optimism surrounding its antibody discovery platform, a new collaboration with Vertex Pharmaceuticals, and upcoming Phase 2 data for ABCL635. The Vertex deal provides $28 million upfront, with potential milestones and royalties, validating ABCL's …

AbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Just Slashed This Year's Revenue Estimates By 22%

Analysts have significantly revised down AbCellera Biologics Inc.'s (NASDAQ:ABCL) revenue estimates for 2026 by 22%, now forecasting US$25 million, which represents a 62% decline year-over-year. Despite this pessimistic outlook, the company's share price has recently risen by 19%. The updated forecasts suggest AbCellera Biologics …

Cellebrite DI (CLBT) Shares Climbed, What Is Driving Attention Now?

Cellebrite DI (CLBT) is gaining investor attention ahead of its Q2 2026 earnings report and following an expanded partnership with SkySafe for drone detection. The company's stock has seen a 25.67% return over 90 days, despite a year-to-date dip, with its recurring revenue model …

Excellence Commercial Property Sets August Board Meeting to Approve Interim Results

Quantinno Capital Management LP Grows Stake in Millicom International Cellular SA $TIGO

Quantinno Capital Management LP significantly increased its stake in Millicom International Cellular SA by 78.1% in the first quarter, now owning 38,205 shares valued at $2.86 million. Other institutions like Goldman Sachs and UBS also acquired new positions in the company. Analyst ratings for …

Transcript : Cello World Limited, Q1 2027 Earnings Call, Aug 10, 2026

AbCellera To Present Phase 2 Results Of ABCL635 For Menopause Symptoms Today

(RTTNews) - AbCellera Biologics Inc. (ABCL) announced that it will release top-line results from its Phase 2 clinical trial from its Phase 2 clinical trial of ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS), commonly known as hot flashes due to menopause, before …

Cellectar Biosciences (CLRB) Sets Q3 2024 Earnings Call for Nov 18

Cellectar Biosciences (NASDAQ: CLRB) will report its third-quarter 2024 financial results and provide a corporate update on November 18, 2024, at 8:30 a.m. ET. Investors can access the conference call via a toll-free number or a webcast, with a replay available on the company's …

Does Omnicell’s Profit Rebound And Higher 2026 Outlook Change The Bull Case For OMCL?

Omnicell, Inc. reported strong Q2 2026 results with increased revenue and net income, alongside upgraded guidance for the full year 2026. This improved profitability and higher revenue outlook strengthen the company's investment narrative, which relies on medication management automation and a growing software and …

RGC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce

Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Regencell Bioscience Holdings Ltd. (NASDAQ:RGC) and its officers. The lawsuit, filed on behalf of investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, alleges the company made materially …

Lineage Cell Therapeutics Q2 Earnings Call Highlights

Millicom International Cellular (TIGO) Stock Looks Strong On Cash Flow Yet Rich On Earnings

Cellebrite DI Ltd. (CLBTW) Analyst insights, Price targets and Recommendations

This article provides a brief overview of Cellebrite DI Ltd. (CLBTW) stock information, showing its current price and a significant daily percentage decrease. It also lists related tickers and general market data, including various indices and commodity prices. The content appears to be a …

Quantinno Capital Management LP Increases Position in Turkcell Iletisim Hizmetleri AS $TKC

Quantinno Capital Management LP significantly increased its stake in Turkcell Iletisim Hizmetleri AS (NYSE:TKC) during the first quarter of 2026, acquiring an additional 518,158 shares, bringing its total holding to 567,357 shares valued at $3.42 million. Despite this increase and similar moves by other …

Briacell Therapeutics Corp (BCTX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Turkcell Iletisim Hizmetleri AS (TKC) Earnings Forecast: Future EPS & Revenue Growth Estimates

Celldex Therapeutics (CLDX) Stock Looks Rich On Book Value But Strong On Returns

Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter Results

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Celldex Therapeutics (CLDX) released its second quarter 2026 results on 6 August, reporting very limited revenue and a wider net loss. This places the stock's …

Cellectis S.A. (EPA:ALCLS) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Analysts have significantly cut their revenue and earnings per share estimates for Cellectis S.A. (EPA:ALCLS) following the company's recent quarterly results. Revenues for 2026 are now expected to decline by 19% to US$51.8m, and losses per share are projected to increase slightly to US$0.87. …

FuelCell Energy (NASDAQ:FCEL) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen has downgraded FuelCell Energy (NASDAQ:FCEL) from a "hold" to a "sell" rating, reflecting mixed analyst opinions though the broader consensus remains "hold" with an average price target of $22.83. This downgrade follows FuelCell Energy missing analyst expectations for both quarterly earnings …

Is Celldex Therapeutics’ (CLDX) Growing Losses With Minimal Revenue a Strategic Bet or Structural Concern?

Celldex Therapeutics, Inc. recently reported second-quarter 2026 results, with revenue falling to US$0.022 million and net loss widening to US$73.5 million, while loss per share from continuing operations increased to US$0.94. Over the first half of 2026, revenue slipped to just US$0.037 million as …

Celldex Therapeutics (CLDX) Stock Trades At A Premium Despite A 102% Return

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Celldex Therapeutics stock has more than doubled over the past year, yet its broader valuation checks lean expensive rather than cheap, which raises …

AbCellera Biologics (ABCL) Is Up 21.4% After First Phase 2 Readout For Novel NK3R Antibody – Has The Bull Case Changed?

AbCellera Biologics (ABCL) saw its stock rise 21.4% following the first Phase 2 readout for its novel NK3R antibody, ABCL635, targeting menopausal vasomotor symptoms. This marks a significant step in AbCellera's shift towards developing internal therapeutic programs, offering an early test of its new …

What Is Celldex Therapeutics (CLDX) Signaling With Its Mixed Pipeline Update?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Celldex Therapeutics (NasdaqCM:CLDX) reported updated clinical pipeline data, including positive Phase 1 results for bispecific antibody CDX-622. The company outlined progress on ongoing Phase 3 …

Cellectar BioSciences (CLRB.US) will release its earnings report before the market opens on August 13.

Cellectar BioSciences (CLRB.US) is scheduled to release its earnings report on August 13. The report will be published before the market opens.

ImmuCell Corp (ICCC) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for ImmuCell Corp (ICCC), including future estimates for EPS and revenue growth. It presents current stock performance data, market capitalization, and indicates that the financial forecasts were updated on August 8, 2026. The content also lists peer comparisons …

AbCellera (NASDAQ:ABCL) Shares Surge Ahead of Monday's ABCL635 Phase 2 Trial Results

AbCellera's shares surged ahead of the release of its ABCL635 Phase 2 trial results on Monday, with the stock gaining 9.7% in after-hours trading, adding an estimated $205 million to its market value. Despite recent quarterly revenue declines, the anticipation of clinical validation for …

Is Cellebrite (CLBT) Using Drone Forensics To Deepen Its AI Cloud Investigation Moat?

Cellebrite DI recently expanded its exclusive partnership with SkySafe to enhance drone detection and airspace intelligence tools for digital investigations, ahead of its Q2 2026 earnings release. This move is seen as strengthening Cellebrite's AI-enabled, cloud-based platform for emerging investigative needs, although investors are …

Noticias de acciones de Fuelcell Energy Inc (FCEL)

Millicom International Cellular Q2 Earnings Call Highlights

Millicom International Cellular reported strong Q2 2026 results, with service revenue up 5.4% organically and adjusted EBITDA reaching a record $1 billion. The company raised its 2026 equity free cash flow guidance to $1.1 billion and approved an additional interim dividend of $1.50 per …

Cellebrite DI Ltd. $CLBT Shares Sold by Royal Bank of Canada

Royal Bank of Canada reduced its stake in Cellebrite DI Ltd. ($CLBT) by 16.3% in the first quarter, selling over 200,000 shares but still retaining a significant holding. Despite this sale, analyst sentiment remains largely positive, with the company holding a "Moderate Buy" consensus …

Omnicell (OMCL) Could Be 40% Undervalued Following Strong Q2 Earnings And Guidance Raised

Omnicell (OMCL) reported strong Q2 2026 earnings, leading to a rebound in its stock price and updated full-year revenue guidance. The company is considered undervalued by Simply Wall St's narrative, with a fair value of $61.29 compared to its current price of $36.81, driven …